Logo image of VRDN

VIRIDIAN THERAPEUTICS INC (VRDN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:VRDN - US92790C1045 - Common Stock

31.8 USD
-0.08 (-0.25%)
Last: 12/9/2025, 8:00:02 PM
31.8 USD
0 (0%)
After Hours: 12/9/2025, 8:00:02 PM
Fundamental Rating

3

VRDN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. While VRDN seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, VRDN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year VRDN has reported negative net income.
VRDN had a negative operating cash flow in the past year.
VRDN had negative earnings in each of the past 5 years.
VRDN had a negative operating cash flow in each of the past 5 years.
VRDN Yearly Net Income VS EBIT VS OCF VS FCFVRDN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

Looking at the Return On Assets, with a value of -52.32%, VRDN is in line with its industry, outperforming 47.65% of the companies in the same industry.
VRDN has a better Return On Equity (-60.04%) than 61.02% of its industry peers.
Industry RankSector Rank
ROA -52.32%
ROE -60.04%
ROIC N/A
ROA(3y)-38.23%
ROA(5y)-47.6%
ROE(3y)-42.28%
ROE(5y)-52.28%
ROIC(3y)N/A
ROIC(5y)N/A
VRDN Yearly ROA, ROE, ROICVRDN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

VRDN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VRDN Yearly Profit, Operating, Gross MarginsVRDN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K

More info and screens

6

2. Health

2.1 Basic Checks

VRDN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VRDN has more shares outstanding
The number of shares outstanding for VRDN has been increased compared to 5 years ago.
Compared to 1 year ago, VRDN has an improved debt to assets ratio.
VRDN Yearly Shares OutstandingVRDN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
VRDN Yearly Total Debt VS Total AssetsVRDN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

VRDN has an Altman-Z score of 20.99. This indicates that VRDN is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of VRDN (20.99) is better than 89.64% of its industry peers.
A Debt/Equity ratio of 0.04 indicates that VRDN is not too dependend on debt financing.
VRDN's Debt to Equity ratio of 0.04 is in line compared to the rest of the industry. VRDN outperforms 40.30% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z 20.99
ROIC/WACCN/A
WACC8.8%
VRDN Yearly LT Debt VS Equity VS FCFVRDN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

VRDN has a Current Ratio of 11.28. This indicates that VRDN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 11.28, VRDN belongs to the top of the industry, outperforming 85.12% of the companies in the same industry.
VRDN has a Quick Ratio of 11.28. This indicates that VRDN is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of VRDN (11.28) is better than 85.12% of its industry peers.
Industry RankSector Rank
Current Ratio 11.28
Quick Ratio 11.28
VRDN Yearly Current Assets VS Current LiabilitesVRDN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

VRDN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.52%, which is quite impressive.
Looking at the last year, VRDN shows a very strong growth in Revenue. The Revenue has grown by 23340.07%.
The Revenue for VRDN have been decreasing by -41.64% on average. This is quite bad
EPS 1Y (TTM)25.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.43%
Revenue 1Y (TTM)23340.07%
Revenue growth 3Y-53.27%
Revenue growth 5Y-41.64%
Sales Q2Q%81958.14%

3.2 Future

VRDN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.75% yearly.
Based on estimates for the next years, VRDN will show a very strong growth in Revenue. The Revenue will grow by 397.69% on average per year.
EPS Next Y-4.7%
EPS Next 2Y0.88%
EPS Next 3Y14.42%
EPS Next 5Y20.75%
Revenue Next Year24826.4%
Revenue Next 2Y1527.21%
Revenue Next 3Y909.35%
Revenue Next 5Y397.69%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VRDN Yearly Revenue VS EstimatesVRDN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
VRDN Yearly EPS VS EstimatesVRDN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -200 -400 -600

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VRDN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VRDN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VRDN Price Earnings VS Forward Price EarningsVRDN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VRDN Per share dataVRDN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A more expensive valuation may be justified as VRDN's earnings are expected to grow with 14.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.88%
EPS Next 3Y14.42%

More info and screens

0

5. Dividend

5.1 Amount

VRDN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIRIDIAN THERAPEUTICS INC

NASDAQ:VRDN (12/9/2025, 8:00:02 PM)

After market: 31.8 0 (0%)

31.8

-0.08 (-0.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/bmo
Earnings (Next)02-25 2026-02-25/amc
Inst Owners99.08%
Inst Owner Change-1.84%
Ins Owners0.04%
Ins Owner Change0%
Market Cap3.03B
Revenue(TTM)70.79M
Net Income(TTM)-301.97M
Analysts85
Price Target40.62 (27.74%)
Short Float %10.09%
Short Ratio6.34
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.05%
Min EPS beat(2)2.88%
Max EPS beat(2)69.21%
EPS beat(4)4
Avg EPS beat(4)22.3%
Min EPS beat(4)2.88%
Max EPS beat(4)69.21%
EPS beat(8)5
Avg EPS beat(8)8.49%
EPS beat(12)7
Avg EPS beat(12)-1.64%
EPS beat(16)9
Avg EPS beat(16)-3.19%
Revenue beat(2)2
Avg Revenue beat(2)101999%
Min Revenue beat(2)68.49%
Max Revenue beat(2)203929%
Revenue beat(4)4
Avg Revenue beat(4)51014.2%
Min Revenue beat(4)0.65%
Max Revenue beat(4)203929%
Revenue beat(8)5
Avg Revenue beat(8)25508.3%
Revenue beat(12)5
Avg Revenue beat(12)16989.2%
Revenue beat(16)7
Avg Revenue beat(16)12756.5%
PT rev (1m)2.11%
PT rev (3m)2.44%
EPS NQ rev (1m)-5.43%
EPS NQ rev (3m)-0.44%
EPS NY rev (1m)7.42%
EPS NY rev (3m)-6.34%
Revenue NQ rev (1m)20389.8%
Revenue NQ rev (3m)26564.1%
Revenue NY rev (1m)61651.7%
Revenue NY rev (3m)55218.2%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 42.87
P/FCF N/A
P/OCF N/A
P/B 6.03
P/tB 6.03
EV/EBITDA N/A
EPS(TTM)-3.21
EYN/A
EPS(NY)-3.89
Fwd EYN/A
FCF(TTM)-3.42
FCFYN/A
OCF(TTM)-3.42
OCFYN/A
SpS0.74
BVpS5.27
TBVpS5.27
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -52.32%
ROE -60.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-38.23%
ROA(5y)-47.6%
ROE(3y)-42.28%
ROE(5y)-52.28%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 79.7%
Cap/Sales 0.52%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.28
Quick Ratio 11.28
Altman-Z 20.99
F-Score2
WACC8.8%
ROIC/WACCN/A
Cap/Depr(3y)191.45%
Cap/Depr(5y)174.87%
Cap/Sales(3y)166.8%
Cap/Sales(5y)103.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.43%
EPS Next Y-4.7%
EPS Next 2Y0.88%
EPS Next 3Y14.42%
EPS Next 5Y20.75%
Revenue 1Y (TTM)23340.07%
Revenue growth 3Y-53.27%
Revenue growth 5Y-41.64%
Sales Q2Q%81958.14%
Revenue Next Year24826.4%
Revenue Next 2Y1527.21%
Revenue Next 3Y909.35%
Revenue Next 5Y397.69%
EBIT growth 1Y-15.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.51%
EBIT Next 3Y11%
EBIT Next 5Y36.92%
FCF growth 1Y-80.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-80.88%
OCF growth 3YN/A
OCF growth 5YN/A

VIRIDIAN THERAPEUTICS INC / VRDN FAQ

What is the fundamental rating for VRDN stock?

ChartMill assigns a fundamental rating of 3 / 10 to VRDN.


What is the valuation status for VRDN stock?

ChartMill assigns a valuation rating of 0 / 10 to VIRIDIAN THERAPEUTICS INC (VRDN). This can be considered as Overvalued.


How profitable is VIRIDIAN THERAPEUTICS INC (VRDN) stock?

VIRIDIAN THERAPEUTICS INC (VRDN) has a profitability rating of 1 / 10.


How financially healthy is VIRIDIAN THERAPEUTICS INC?

The financial health rating of VIRIDIAN THERAPEUTICS INC (VRDN) is 6 / 10.


Can you provide the expected EPS growth for VRDN stock?

The Earnings per Share (EPS) of VIRIDIAN THERAPEUTICS INC (VRDN) is expected to decline by -4.7% in the next year.